Open study on the efficacy and safety of long-term use of SURGAM-SR (sustained-release form of tiaprofenic acid) in rheumatoid arthritis patients

1993 ◽  
Vol 2 (1) ◽  
pp. 63-70 ◽  
Author(s):  
W. Kean ◽  
W. Buchanan ◽  
J. P. Pelletier ◽  
B. Haraoui ◽  
D. Choquette ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Sustained Release ◽  
Open Study ◽  
Tiaprofenic Acid ◽  
Efficacy And Safety ◽  
Sustained Release Form ◽  
Release Form

Human Availability Studies of Five Vitamins in Sustained Release Form

1961 ◽  
Vol 9 (3) ◽  
pp. 324-330 ◽  
Author(s):  
SAMUEL M. GREENBERG ◽  
JOHN F. HERNDON ◽  
DONALD R. MACDONNELL ◽  
THOMAS L. FLANAGAN ◽  
AMADEO BONDI
Keyword(s):  
Sustained Release ◽  
Sustained Release Form ◽  
Release Form

Efficacy and Tolerance of Tiaprofenic Acid During Long Term Administration to Rheumatoid Arthritis Patients1

Drugs ◽  
1988 ◽  
Vol 35 (Supplement 1) ◽  
pp. 101-106 ◽  
Author(s):  
T. Nagaya ◽  
S. Niwa ◽  
S. Harada ◽  
Y. Konishi
Keyword(s):  
Rheumatoid Arthritis ◽  
Tiaprofenic Acid ◽  
Term Administration

AB0458 Tocilizumab: Analysis of Long-Term Efficacy and Safety in Rheumatoid Arthritis Patients: Table 1

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 1049.1-1049
Author(s):  
I. Chalmeta Verdejo ◽  
L. González Puig ◽  
E. Labrador Sánchez ◽  
C.M. Feced Olmos ◽  
E. Grau Garcia ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Efficacy And Safety ◽  
Term Efficacy

Trial of a Sustained Release Form of Amitriptyline (Lentizol) in the Treatment of Depressive Illness

1973 ◽  
Vol 123 (572) ◽  
pp. 69-71 ◽  
Author(s):  
G. Sedman
Keyword(s):  
Single Dose ◽  
Sustained Release ◽  
Dosage Level ◽  
Depressive Illness ◽  
Double Blind ◽  
Sustained Release Form ◽  
Release Form

The advantages of a new sustained release form of amitriptyline (Lentizol) which can be given in a single dose for the treatment of depressive illness have recently been described by Sims (1972) and Haider (1972). This paper reports a similar double blind cross-over trial in the treatment of depressive illness (ICD 296) of the same substance compared against conventional amitriptyline at an overall higher dosage level.

scholarly journals Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

BioDrugs ◽  
2019 ◽  
Vol 33 (1) ◽  
pp. 79-91 ◽  
Author(s):  
Chang-Hee Suh ◽  
Dae Hyun Yoo ◽  
Alfredo Berrocal Kasay ◽  
Elia Chalouhi El-Khouri ◽  
Francisco Fidenci Cons Molina ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Phase Iii Trial ◽  
Term Efficacy

scholarly journals Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder

2012 ◽  
Vol 69 (2) ◽  
pp. 201-204 ◽  
Author(s):  
Aneta Lakic
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Depressive Symptoms ◽  
Side Effects ◽  
Sustained Release ◽  
Attention Deficit ◽  
Depressive Symptomatology ◽  
Hyperactivity Disorder ◽  
Sustained Release Form ◽  
The Brain ◽  
Release Form

Introduction. Hyperkinetic disorder or attention-deficit hyperactivity disorder (ADHD) is a clinical entity consisting of a cluster of symptoms including hyperactivity, attention disorder and impulse control disorder group. In the context of ADHD etiology we may say that genetic, clinical and imaging studies point out a disruption of the brain dopamine system, which is corroborated by the clinical effectiveness of stimulant drugs, which increase extracellular dopamine in the brain. Basically, it is a biological and not psychological disorder, which is important both for the comprehension and therapeutical approach to this problem. Today, the best recommended approach regarding children with ADHD is a combination of two therapeutic modalities: pharmacotherapy and behavioral treatment. The first-choice drugs for this disorder belong to the group of sympathomimetics - psychostimulants and atomoxetine (more recently). As the firstchoice therapy, methylphenydate in sustained release form has numerous advantages. Like all drugs, methylphenidate has its unwanted side effects. Most common are: loss of appetite, weight loss, sleeping disorders, irritability, headache. These side effects are well-known and documented in the literature. By analysing the available literature we have found cases of psychiatric side effects such as: psychosis, mania, visual hallucinations, agitation, suicidal ideas. We have not found examples of ADHD in children who use increased dosage of sustained release of methylphenidate leading to depressive symptomatology. On the other side, methylphenidate may be prescribed for off-label use in treatmentresistant cases of depression. Case report. The case of a 7- year-old boy diagnosed with ADHD was on a minimal dose of sustained release form of methylphenidate. After initial titration of the drug, i.e. after raising the dose to the next level the boy developed clinical signs of depression. The treatment was ceased and depressive symptoms were withdrawed. Conclusion. Manifestation of depressive symptomatology after dose increasement of sustained release form of methylphenidate in a 7-year-old boy with ADHD represents an uncommon side effect. Precise drug activity mechanisms responsible for the appearance of these symptoms remains to be explained.

Sign in / Sign up

Export Citation Format

Share Document